non glp 1 oral medications Foundayo (orforglipron) – First Non-Peptide GLP-1 RA FDA-approved April 2026 for chronic weight management. Once-daily tablet with no fasting requirement, stepwise dosing up to 17.2 mg, and meaningful weight reduction in WLP-1: Oral GLP-1 Support

Glucagon-like peptide-1 agonists (GLP-1s) have been in the spotlight as demand has grown to support type 2 diabetes and weight loss

These combined actives function as a metabolic booster and weight manager, helping encourage efficient metabolic activity within a wellness routine

Notwithstanding the buzz surrounding the novel weight loss treatments, which is vividly playing out on social media and beyond, capturing this commercial opportunity will still require an orderly, rigorous approach to create and shape a new market

In an investigative report in partnership with KFF Health News, NBC News Anne Thompson reports on the growing cases of overdoses involving GLP-1 weight loss drugs.